Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for ARDX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 -1.68M
March 31, 2026 -5.442M
December 31, 2025 -0.557M
September 30, 2025 -2.814M
June 30, 2025 -0.988M
March 31, 2025 -1.482M
December 31, 2024 -0.612M
September 30, 2024 -2.697M
June 30, 2024 -1.608M
March 31, 2024 -3.221M
December 31, 2023 -0.102M
September 30, 2023 -57.87M
June 30, 2023 -11.52M
March 31, 2023 -50.92M
December 31, 2022 -9.206M
September 30, 2022 -34.48M
June 30, 2022 -22.14M
March 31, 2022 -6.004M
December 31, 2021 -33.96M
September 30, 2021 -5.105M
June 30, 2021 -28.72M
March 31, 2021 -34.77M
December 31, 2020 -21.31M
September 30, 2020 -0.798M
June 30, 2020 -0.204M
Date Value
March 31, 2020 -0.591M
December 31, 2019 -155.06M
September 30, 2019 -0.213M
June 30, 2019 -0.005M
March 31, 2019 -0.20M
December 31, 2018 0.001M
September 30, 2018 -0.191M
June 30, 2018 -53.77M
March 31, 2018 -0.301M
December 31, 2017 -0.01M
September 30, 2017 -0.049M
June 30, 2017 -0.218M
March 31, 2017 -0.408M
December 31, 2016 -0.027M
September 30, 2016 -109.87M
June 30, 2016 -0.188M
March 31, 2016 -81.12M
December 31, 2015 -0.014M
September 30, 2015 0.003M
June 30, 2015 -74.68M
March 31, 2015 -0.296M
December 31, 2014 -0.066M
September 30, 2014 -0.003M
June 30, 2014 0.00
March 31, 2014 0.00

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
REGENXBIO, Inc. -19.38M
ACADIA Pharmaceuticals, Inc. -10.49M
Alnylam Pharmaceuticals, Inc. -33.56M
Anika Therapeutics, Inc. 0.643M
Savara, Inc. -0.189M